Complement C3 Activation Is Required for Antiphospholipid Antibody-induced Fetal Loss

DOI PDF 被引用文献14件
  • V. Michael Holers
    1Departments of Medicine and Immunology, University of Colorado Health Sciences Center, Denver, CO 80262
  • Guillermina Girardi
    2Department of Medicine, Hospital for Special Surgery-Weill Medical College, Cornell University, New York, NY 10021
  • Lian Mo
    2Department of Medicine, Hospital for Special Surgery-Weill Medical College, Cornell University, New York, NY 10021
  • Joel M. Guthridge
    1Departments of Medicine and Immunology, University of Colorado Health Sciences Center, Denver, CO 80262
  • Hector Molina
    3Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110
  • Silvia S. Pierangeli
    4Department of Microbiology-Immunology, Morehouse School of Medicine, Atlanta, GA 30310
  • Ricardo Espinola
    4Department of Microbiology-Immunology, Morehouse School of Medicine, Atlanta, GA 30310
  • Liu E. Xiaowei
    4Department of Microbiology-Immunology, Morehouse School of Medicine, Atlanta, GA 30310
  • Dailing Mao
    3Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110
  • Christopher G. Vialpando
    1Departments of Medicine and Immunology, University of Colorado Health Sciences Center, Denver, CO 80262
  • Jane E. Salmon
    2Department of Medicine, Hospital for Special Surgery-Weill Medical College, Cornell University, New York, NY 10021

抄録

<jats:p>The antiphospholipid syndrome (APS) is characterized by recurrent fetal loss, vascular thrombosis, and thrombocytopenia occurring in the presence of antiphospholipid (aPL) antibodies. The pathogenesis of fetal loss and tissue injury in APS is incompletely understood, but is thought to involve platelet and endothelial cell activation as well as procoagulant effects of aPL antibodies acting directly on clotting pathway components. Recent studies have shown that uncontrolled complement activation in the placenta leads to fetal death in utero. We hypothesized that aPL antibodies activate complement in the placenta, generating split products that mediate placental injury and lead to fetal loss and growth retardation. To test this hypothesis, we used a murine model of APS in which pregnant mice are injected with human IgG containing aPL antibodies. We found that inhibition of the complement cascade in vivo, using the C3 convertase inhibitor complement receptor 1–related gene/protein y (Crry)-Ig, blocks fetal loss and growth retardation. Furthermore, mice deficient in complement C3 were resistant to fetal injury induced by aPL antibodies. While antigenic epitopes recognized by aPL antibodies are important in the pathogenesis of APS, our data show that in vivo complement activation is required for aPL antibody-induced fetal loss and growth retardation.</jats:p>

収録刊行物

被引用文献 (14)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ